ClinicalTrials.gg
RecruitingNCT07938034Updated Nov 16, 2026

A Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal Function

A Phase 1 interventional study of SYH2053 in Renal Impairment, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies in Renal Insufficiency with a site in China — 16 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · China.

Planned enrollment
34th of 48
24 · median 41
Started
2026
with 8 others
Phase 1
22 of 61
4 open now
Primary completion
2027-07
later than 8 of 15 live
Registered
58th of 61
by date

Among the 61 studies in Renal Insufficiency with a site in China, this one is the 34th largest by planned enrollment of the 48 interventional ones that give a count, is one of 9 that started in 2026, is one of 22 in phase 1, reaches primary completion later than 8 of the 15 other live ones, and was the 58th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

16 of the 61 studies in Renal Insufficiency with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Renal Insufficiency with a site in China, or all of them as a file.
02

Study summary

This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with moderate, and severe renal impairment compared to participants with normal renal function.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 75 years (inclusive) at the time of screening, males or females.
  • Body weight ≥ 45.0 kg for females or ≥ 50.0 kg for males, and (BMI) between 18.0 and 35.0 kg/m² (inclusive), where BMI = weight (kg) / height² (m²).
  • LDL-C ≥ 70 mg/dL (1.8 mmol/L) at the screening visit.
  • Participants of , as well as their partners, must agree to use effective and reliable measures from the signing of the form until at least 6 months after study drug administration.
  • Participants must be able to communicate well with the investigator and be willing and able to comply with all protocol requirements throughout the study.
  • For participants with renal impairment: if lipid-lowering agents (including statins, ezetimibe, fibrates, etc.) have been used prior to screening, the dose must have been stable for at least 4 weeks, or the agent must have been discontinued for at least 2 weeks. During the study period, the dose and frequency of previous lipid-lowering therapy are planned to remain unchanged.
  • For participants with renal impairment: participants must have stable renal function, and the must meet the corresponding renal function classification criteria for the respective group, i.e.: Moderate renal impairment: 30 mL/min ≤ eGFR \< 60 mL/min; Severe renal impairment: 15 mL/min ≤ eGFR \< 30 mL/min
  • For participants with renal impairment: physical examination, vital signs, laboratory tests, 12-lead , chest X-ray, abdominal ultrasound, and other examination results must be judged by the investigator as suitable for participation in this study.
  • For participants with normal renal function: no use of any medication (including over-the-counter supplements and vitamins) within 4 weeks prior to screening.
  • For participants with normal renal function: 90 mL/min ≤ eGFR \< 130 mL/min.
  • For participants with normal renal function: physical examination, vital signs, laboratory tests, 12-lead ECG, chest X-ray, abdominal ultrasound, and other examination results must be normal or show abnormalities without clinical significance.

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic diseases, such as anaphylactic shock, systemic severe urticaria, etc., or a history of allergy to oligonucleotide drugs.
  • Any of the following cardiovascular or cerebrovascular events within 6 months prior to screening: unstable angina, myocardial infarction, or cerebrovascular accident (e.g., stroke), coronary artery bypass grafting; or other cardiovascular and cerebrovascular diseases that, in the investigator's assessment, make the participant unsuitable for participation in this clinical trial.
  • Prolonged Fridericia- interval (QTcF) on a 12-lead at screening (QTcF: >450 ms for males, >470 ms for females); or severe cardiac arrhythmias (e.g., recurrent or symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia) that, in the investigator's assessment, make the participant unsuitable for participation in this clinical trial.
  • Prior surgery that may affect drug distribution, metabolism, or excretion (e.g., liver or kidney surgery), or anticipated hospitalization during the study period due to surgery or other reasons.
  • Meeting any of the following at screening:

    1. For participants with renal impairment: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; for participants with normal renal function: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg;
    2. Triglycerides >5.7 mmol/L.
  • For participants with renal impairment: (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) >2.5 × (ULN), or total >2 × ULN; for participants with normal renal function: ALT, AST, GGT, or total bilirubin >1.5 × ULN.
  • Diagnosis of within 5 years prior to screening (except for adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, cervical carcinoma in situ, and ductal carcinoma in situ of the breast).
  • Use of PCSK9 monoclonal antibody drugs or oral PCSK9 inhibitors within 180 days prior to screening; use of Leqvio® or any other RNA-based therapy for lipid-lowering purposes within 2 years prior to screening, including but not limited to siRNA or antisense oligonucleotide therapy.
  • Participation in another clinical trial within 3 months prior to screening (i.e., less than 3 months since the last dose of the product).
  • Average daily smoking of more than 5 cigarettes (or equivalent tobacco in e-cigarettes) within 3 months prior to screening, and/or unwillingness to refrain from using any tobacco products during the study period.
  • Regular alcohol consumption within 6 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360 mL of beer with 5% alcohol content, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine with 12% alcohol content), and/or inability to abstain from alcohol during the study period, and/or a positive breath alcohol test.
  • History of drug abuse, and/or a positive urine drug screening test.
  • Regular consumption of caffeine exceeding 600 mg per day within 3 months prior to screening (1 cup of coffee contains approximately 100 mg of caffeine, 1 cup of tea contains approximately 30 mg of caffeine, and 1 can of cola contains approximately 20 mg of caffeine), or planned use of caffeine-containing products or medications within 24 hours prior to study drug administration.
  • Blood loss or blood donation exceeding 400 mL within 3 months prior to dosing, and/or donation within 2 weeks prior to dosing.
  • Pregnant or lactating women; female participants of with a serum pregnancy test result exceeding the upper limit of normal at screening; or female participants who had unprotected sexual intercourse within 2 weeks prior to screening.
  • For participants with normal renal function: positive for any of surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody, or Treponema pallidum antibody; for participants with renal impairment: positive for HBsAg with detectable HBV-DNA, positive for HCV antibody with detectable HCV-RNA, positive for HIV antibody, or positive for Treponema pallidum antibody, meeting any of the above criteria.
  • Currently receiving renal replacement therapy (including kidney transplantation, hemodialysis, etc.).
  • Presence of urinary incontinence at screening.
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    SYH2053(normal renal function)

    Participants will receive a single dose of SYH2053 administered by SC injection on Day 1. Normal renal function is defined as estimate glomerular filtration rate (eGFR) of ≥90 milliliter (mL)/minute (min) and \<130 mL/min.

    Drug: SYH2053

  • Experimental
    SYH2053(moderate renal function)

    Participants will receive a single dose of SYH2053 administered by SC injection on Day 1. Moderate renal function is defined as eGFR of ≥30 mL/min and \<60 mL/min.

    Drug: SYH2053

  • Experimental
    SYH2053(severe renal function)

    Participants will receive a single dose of SYH2053 administered by SC injection on Day 1. Severe renal function is defined as eGFR of ≥15 mL/min and \<30 mL/min.

    Drug: SYH2053

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Time Frame: Pre-dose and multiple timepoints up to 4 days

  2. Area under the curve of the plasma concentration (AUC)

    Time frame: Pre-dose and multiple timepoints up to 4 days

  3. Time to reach maximum plasma concentration (Tmax)

    Time frame: Pre-dose and multiple timepoints up to 4 days

  4. Terminal half-life (t1/2)

    Time frame: Pre-dose and multiple timepoints up to 4 days

  5. Apparent total clearance (CL/F)

    Time frame: Pre-dose and multiple timepoints up to 4 days

  6. Apparent volume of distribution (Vz/F)

    Time frame: Pre-dose and multiple timepoints up to 4 days

  7. Amount excreted unchanged in urine (Ae) of SYH2053 over 72 hours post-dose

    Time frame: Pre-dose and multiple timepoints up to 4 days

  8. Fraction excreted (fe) of SYH2053 over 72 hours post-dose

    Time frame: Pre-dose and multiple timepoints up to 4 days

  9. Renal clearance (CLr) of SYH2053

    Time frame: Pre-dose and multiple timepoints up to 4 days

  10. The serum Low-density lipoprotein cholesterol (LDL-C) level

    Time frame: through study completion, an average of 6 months

  11. The serum PCSK9 level

    Time frame: through study completion, an average of 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 12 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Nov 16, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Jul 15, 2027
CompletionEst.
Sep 15, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07938034
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jul 15, 2026
Primary completion
Jul 15, 2027 (estimated)
Completion
Sep 15, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
0311-69085587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYH2053

Start the discussion